{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:08:00Z","timestamp":1792804080760,"version":"4.5.0"},"reference-count":81,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune system to fight cancer cells. Their use is often limited by the development of autoimmune toxicities, which can affect multiple organ systems and are referred to as immune-related adverse events (irAE). Among these are rheumatologic irAE, including inflammatory arthritis, myositis, vasculitis, and others. Rheumatologic irAE seem to be different from irAE in other organs and from traditional autoimmune diseases in that they can occur early or have delayed onset, and can persist chronically, even after cancer therapy is terminated. Because immune checkpoint inhibitors are increasingly used for many types of cancer, it is important for oncologists and rheumatologists to recognize and manage toxicities early. In this review, we discuss currently approved immune checkpoint inhibitors and their mechanisms of action and systemic toxicities, with a focus on the management and effect on further cancer therapy of rheumatic irAE.<\/jats:p>","DOI":"10.3899\/jrheum.190084","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T12:17:34Z","timestamp":1563193054000},"page":"166-175","source":"Crossref","is-referenced-by-count":73,"title":["Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist"],"prefix":"10.3899","volume":"47","author":[{"given":"Shahin","family":"Jamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-9825","authenticated-orcid":false,"given":"Aurore","family":"Fifi-Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"2020020109251864000_47.2.166.1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrclinonc.2016.65","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"15_suppl","key":"2020020109251864000_47.2.166.2","doi-asserted-by":"crossref","first-page":"TPS8578","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8578","article-title":"CheckMate 331: an open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC)","volume":"34","author":"Horn","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020020109251864000_47.2.166.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"2020020109251864000_47.2.166.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"2020020109251864000_47.2.166.5","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875"},{"key":"2020020109251864000_47.2.166.6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2020020109251864000_47.2.166.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001"},{"key":"2020020109251864000_47.2.166.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2020020109251864000_47.2.166.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2020020109251864000_47.2.166.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"2020020109251864000_47.2.166.11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2020020109251864000_47.2.166.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2020020109251864000_47.2.166.13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40259-016-0204-3","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors","volume":"30","author":"Day","year":"2016","journal-title":"BioDrugs"},{"key":"2020020109251864000_47.2.166.14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"2020020109251864000_47.2.166.15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000321"},{"key":"2020020109251864000_47.2.166.16","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2020020109251864000_47.2.166.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209595"},{"key":"2020020109251864000_47.2.166.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257"},{"key":"2020020109251864000_47.2.166.19","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0417-8"},{"key":"2020020109251864000_47.2.166.20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2020020109251864000_47.2.166.21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.autrev.2018.01.010","article-title":"Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Tocut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2020020109251864000_47.2.166.22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2020020109251864000_47.2.166.23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000412"},{"key":"2020020109251864000_47.2.166.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.6481"},{"key":"2020020109251864000_47.2.166.25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2020020109251864000_47.2.166.26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology"},{"key":"2020020109251864000_47.2.166.27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"2020020109251864000_47.2.166.28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020020109251864000_47.2.166.29","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3359"},{"key":"2020020109251864000_47.2.166.30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","article-title":"Nivolumab-induced myositis: A case report and a literature review","volume":"387","author":"Bourgeois-Vionnet","year":"2018","journal-title":"J Neurol Sci"},{"key":"2020020109251864000_47.2.166.31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2020020109251864000_47.2.166.32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10067-018-4373-y","article-title":"Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy","volume":"38","author":"Tauber","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2020020109251864000_47.2.166.33","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1212\/NXI.0000000000000464","article-title":"Granulomatous myositis induced by anti\u2013PD-1 monoclonal antibodies","volume":"5","author":"Uchio","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"2020020109251864000_47.2.166.34","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2020020109251864000_47.2.166.35","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"2020020109251864000_47.2.166.36","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.229"},{"key":"2020020109251864000_47.2.166.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213777"},{"key":"2020020109251864000_47.2.166.38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2020020109251864000_47.2.166.39","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"2020020109251864000_47.2.166.40","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0258-x"},{"key":"2020020109251864000_47.2.166.41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor\u2013associated myositis","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"2020020109251864000_47.2.166.42","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100007939"},{"key":"2020020109251864000_47.2.166.43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CMR.0000000000000485","article-title":"Hepatitis is the new myositis","volume":"28","author":"Roberts","year":"2018","journal-title":"Melanoma Res"},{"key":"2020020109251864000_47.2.166.44","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2020020109251864000_47.2.166.45","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2020020109251864000_47.2.166.46","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0443-6"},{"key":"2020020109251864000_47.2.166.47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew063"},{"key":"2020020109251864000_47.2.166.48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.5095"},{"key":"2020020109251864000_47.2.166.49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0042-102668","article-title":"Intraocular inflammation associated with new therapies for cutaneous melanoma \u2013 case series and review","volume":"233","author":"Fierz","year":"2016","journal-title":"Klin Monbl Augenheilkd"},{"key":"2020020109251864000_47.2.166.50","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0041-1"},{"key":"2020020109251864000_47.2.166.51","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jdcr.2018.05.020","article-title":"Checkpoint inhibitor\u2013associated cutaneous small vessel vasculitis","volume":"4","author":"Castillo","year":"2018","journal-title":"JAAD Case Reports"},{"key":"2020020109251864000_47.2.166.52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/CJI.0000000000000118","article-title":"Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease","volume":"39","author":"Maul","year":"2016","journal-title":"J Immunother"},{"key":"2020020109251864000_47.2.166.53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616848114"},{"key":"2020020109251864000_47.2.166.54","unstructured":"US Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017. [Internet. Accessed October 31, 2019.] Available from: ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"2020020109251864000_47.2.166.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2020020109251864000_47.2.166.56","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2020020109251864000_47.2.166.57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"2020020109251864000_47.2.166.58","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2020020109251864000_47.2.166.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.007"},{"key":"2020020109251864000_47.2.166.60","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211560"},{"key":"2020020109251864000_47.2.166.61","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2020020109251864000_47.2.166.62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti\u2013programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"key":"2020020109251864000_47.2.166.63","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214336"},{"key":"2020020109251864000_47.2.166.64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"2020020109251864000_47.2.166.65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5716"},{"key":"2020020109251864000_47.2.166.66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"2020020109251864000_47.2.166.67","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020020109251864000_47.2.166.68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2289"},{"key":"2020020109251864000_47.2.166.69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3080"},{"key":"2020020109251864000_47.2.166.70","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156e47e"},{"key":"2020020109251864000_47.2.166.71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0187"},{"key":"2020020109251864000_47.2.166.72","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328341edff"},{"key":"2020020109251864000_47.2.166.73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2020020109251864000_47.2.166.74","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma","volume":"4","author":"Shoushtari","year":"2018","journal-title":"JAMA Oncol"},{"key":"2020020109251864000_47.2.166.75","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"2020020109251864000_47.2.166.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019"},{"key":"2020020109251864000_47.2.166.77","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"2020020109251864000_47.2.166.78","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"2020020109251864000_47.2.166.79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"2020020109251864000_47.2.166.80","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2020020109251864000_47.2.166.81","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.190084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T12:25:59Z","timestamp":1580559959000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.190084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,1]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.3899\/jrheum.190084"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.190084","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]}}}